24.07.2008 09:00:00
|
Thermo Fisher Scientific Reports Record 2008 Second Quarter Results
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving
science, reported that revenues increased 14% to a record $2.71 billion
in the second quarter of 2008, over $2.39 billion in the 2007 quarter.
Currency translation increased revenues by 4%, and acquisitions, net of
divestitures, increased revenues by 2%. GAAP diluted earnings per share
(EPS) were $.57 in 2008, versus $.37 in the year-ago period. GAAP
operating income for the 2008 quarter was $330.2 million, compared with
$243.0 million in 2007, and GAAP operating margin was 12.2%, compared
with 10.2% a year ago.
Adjusted EPS grew 22% to $.79 in the second quarter of 2008, over $.65
in the 2007 quarter. Adjusted operating income for the 2008 quarter
increased 18% versus 2007 results, and adjusted operating margin
expanded 60 basis points to 17.6%, compared with adjusted operating
margin of 17.0% in the 2007 period. Adjusted EPS, adjusted operating
income and adjusted operating margin are non-GAAP measures that exclude
certain items detailed later in this press release under the heading "Use
of Non-GAAP Financial Measures.” Highlights
Revenues grew 14%
Adjusted EPS rose 22%
Adjusted operating income increased 18%
Adjusted operating margin expanded 60 basis points
Breakthrough instrument systems launched at American Society of Mass
Spectrometry (ASMS) conference
Recent acquisitions strengthened analytical and environmental
instrument capabilities in India, and expanded bioreagents portfolio
for life sciences research
"We’re pleased to
report another record quarter, with excellent top line performance,
significant growth in adjusted EPS and good margin expansion,”
said Marijn E. Dekkers, president and chief executive officer of Thermo
Fisher Scientific. "Our strong results to
date are right in line with our expectations, and position us well to
achieve our financial goals for all of 2008.
"Our excellent growth was driven by robust
demand in our scientific instruments, specialty diagnostics and
biopharma services businesses, as well as ongoing strong performance in
Asia overall. We continue to reinforce our technology leadership, and
had a very successful showing at ASMS that included two new breakthrough
instruments designed to give scientists advanced tools for a range of
research applications. We also recently made several strategic
acquisitions to strengthen our position in the growing analytical and
environmental markets in India, and to expand our portfolio of
bioscience reagents so we can provide more integrated solutions to life
sciences researchers around the world.”
Mr. Dekkers added, "We remain confident in
the full-year guidance we gave last quarter, and are therefore
maintaining our revenue guidance of $10.6 to $10.7 billion for 2008,
resulting in 9 to 10% growth over 2007. We are increasing the low end of
our adjusted EPS guidance for the year by $.04, to a range of $3.11 to
$3.17, which would lead to 17 to 20% growth over our 2007 results.”
(The 2008 guidance does not include any future acquisitions or
divestitures, and is based on present currency exchange rates. In
addition, the adjusted EPS estimate excludes amortization expense for
acquisition-related intangible assets and certain other items detailed
later in this press release under the heading "Use
of Non-GAAP Financial Measures.”)
Management uses adjusted operating results to monitor and evaluate
performance of the company’s business
segments.
Analytical Technologies Segment
Revenues in the Analytical Technologies Segment grew 14% in the second
quarter of 2008 to $1.16 billion, compared with revenues of $1.02
billion in the 2007 quarter. Adjusted operating income increased 21% in
the second quarter of 2008, and adjusted operating margin rose to 21.1%,
versus 19.8% in the 2007 period.
Laboratory Products and Services Segment
In the Laboratory Products and Services Segment, revenues grew 14% in
the second quarter of 2008 to $1.66 billion, compared with revenues of
$1.45 billion in the 2007 quarter. Adjusted operating income increased
14% in the second quarter of 2008, and adjusted operating margin was
14.0% in both periods.
Use of Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with
generally accepted accounting principles (GAAP), we use certain non-GAAP
financial measures, including adjusted EPS, adjusted operating income
and adjusted operating margin, which exclude restructuring and other
costs/income and amortization of acquisition-related intangible assets.
Adjusted EPS also excludes certain other gains and losses, tax
provisions/benefits related to the previous items, benefits from tax
credit carryforwards, the impact of significant tax audits or events and
discontinued operations. We exclude the above items because they are
outside of our normal operations and/or, in certain cases, are difficult
to forecast accurately for future periods. We believe that the use of
non-GAAP measures helps investors to gain a better understanding of our
core operating results and future prospects, consistent with how
management measures and forecasts the company’s
performance, especially when comparing such results to previous periods
or forecasts.
For example:
We exclude costs and tax effects associated with restructuring
activities, such as reducing overhead and consolidating facilities in
connection with the Fisher merger. We believe that the costs related to
these restructuring activities are not indicative of our normal
operating costs.
We exclude certain acquisition-related costs, including charges for the
sale of inventories revalued at the date of acquisition and professional
fees related to the merger with Fisher. We exclude these costs because
we do not believe they are indicative of our normal operating costs.
We exclude the expense and tax effects associated with the amortization
of acquisition-related intangible assets because a significant portion
of the purchase price for acquisitions may be allocated to intangible
assets that have lives of 5 to 20 years. Our adjusted EPS estimate for
2008 excludes approximately $.90 of expense for the amortization of
acquisition-related intangible assets for acquisitions completed through
the second quarter of 2008. Exclusion of the amortization expense allows
comparisons of operating results that are consistent over time for both
our newly acquired and long-held businesses and with both acquisitive
and non-acquisitive peer companies.
We also exclude certain gains/losses and related tax effects, benefits
from tax credit carryforwards and the impact of significant tax audits
or events (such as the one-time effect on deferred tax balances of
enacted changes in tax rates), which are either isolated or cannot be
expected to occur again with any regularity or predictability and that
we believe are not indicative of our normal operating gains and losses.
For example, we exclude gains/losses from items such as the sale of a
business or real estate, gains or losses on significant
litigation-related matters, gains on curtailments of pension plans, the
early retirement of debt and debt facilities, and discontinued
operations.
Thermo Fisher’s management uses these
non-GAAP measures, in addition to GAAP financial measures, as the basis
for measuring the company’s core operating
performance and comparing such performance to that of prior periods and
to the performance of our competitors. Such measures are also used by
management in their financial and operating decision-making and for
compensation purposes.
The non-GAAP financial measures of Thermo Fisher’s
results of operations included in this press release are not meant to be
considered superior to or a substitute for Thermo Fisher’s
results of operations prepared in accordance with GAAP. Reconciliations
of such non-GAAP financial measures to the most directly comparable GAAP
financial measures are set forth in the accompanying tables. Thermo
Fisher’s earnings guidance, however, is only
provided on an adjusted basis. It is not feasible to provide GAAP EPS
guidance because the items excluded, other than the amortization
expense, are difficult to predict and estimate and are primarily
dependent on future events, such as acquisitions and decisions
concerning the location and timing of facility consolidations.
Conference Call
Thermo Fisher Scientific will hold its earnings conference call today,
July 24, at 9:00 a.m. Eastern time. To listen, dial (866) 793-1301
within the U.S. or (703) 639-1307 outside the U.S., and use conference
ID 1212657. You may also listen to the call live on our Website, www.thermofisher.com,
by clicking on "Investors.”
You will find this press release, including the accompanying
reconciliation of non-GAAP financial measures and related information,
in that section of our Website under "Financial
Results.” An audio archive of the call will
be available under "Webcasts and Presentations”
through Friday, August 29, 2008.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science, enabling our customers to make the world healthier, cleaner and
safer. With annual revenues of $10 billion, we have more than 30,000
employees and serve over 350,000 customers within pharmaceutical and
biotech companies, hospitals and clinical diagnostic labs, universities,
research institutions and government agencies, as well as environmental
and industrial process control settings. Serving customers through two
premier brands, Thermo Scientific and Fisher Scientific, we help solve
analytical challenges from routine testing to complex research and
discovery. Thermo Scientific offers customers a complete range of
high-end analytical instruments as well as laboratory equipment,
software, services, consumables and reagents to enable integrated
laboratory workflow solutions. Fisher Scientific provides a complete
portfolio of laboratory equipment, chemicals, supplies and services used
in healthcare, scientific research, safety and education. Together, we
offer the most convenient purchasing options to customers and
continuously advance our technologies to accelerate the pace of
scientific discovery, enhance value for customers and fuel growth for
shareholders and employees alike. Visit www.thermofisher.com.
The following constitutes a "Safe Harbor”
statement under the Private Securities Litigation Reform Act of 1995:
This press release contains forward-looking statements that involve a
number of risks and uncertainties. Important factors that could cause
actual results to differ materially from those indicated by such
forward-looking statements are set forth in the company’s
Quarterly Report on Form 10-Q for the quarter ended March 29, 2008,
under the caption "Risk Factors,”
which is on file with the Securities and Exchange Commission (SEC) and
available in the "Investors”
section of our Website under the heading "SEC
Filings.” Important factors that could cause
actual results to differ materially from those indicated by
forward-looking statements include risks and uncertainties relating to:
competition and its effect on pricing, spending, third-party
relationships and revenues; the need to develop new products and adapt
to significant technological change; implementation of strategies for
improving internal growth; use and protection of intellectual property;
dependence on customers’ capital spending
policies and government funding policies; realization of potential
future savings from new productivity initiatives; general worldwide
economic conditions and related uncertainties; the effect of changes in
governmental regulations; the effect of exchange rate fluctuations on
international operations; the effect of laws and regulations governing
government contracts; the effect of competing with certain of our
customers and suppliers; and the effect of rapid changes in the
healthcare industry. While we may elect to update forward-looking
statements at some point in the future, we specifically disclaim any
obligation to do so, even if our estimates change and, therefore, you
should not rely on these forward-looking statements as representing our
views as of any date subsequent to today.
Consolidated Statement of Income (unaudited) (a)(b)
Three Months Ended
(In millions except per share amounts)
June 28,2008
% ofRevenues
June 30,2007
% ofRevenues
Revenues
$
2,709.6
$
2,385.9
Costs and Operating Expenses:
Cost of revenues (c)
1,590.8
58.7
%
1,419.1
59.5
%
Selling, general and administrative expenses
578.0
21.3
%
514.7
21.6
%
Amortization of acquisition-related intangible assets
151.6
5.6
%
142.1
6.0
%
Research and development expenses
64.4
2.4
%
58.7
2.5
%
Restructuring and other costs (income), net (d)
(5.4
)
-0.2
%
8.3
0.3
%
2,379.4
87.8
%
2,142.9
89.8
%
Operating Income
330.2
12.2
%
243.0
10.2
%
Interest Income
15.1
10.6
Interest Expense
(36.6
)
(33.2
)
Other (Expense) Income, Net
(1.2
)
1.9
Income from Continuing Operations Before Income Taxes
307.5
222.3
Provision for Income Taxes (e)
(61.2
)
(34.4
)
Income from Continuing Operations
246.3
187.9
Gain (Loss) on Disposal of Discontinued Operations (includes
income tax provision of $1.9 and $1.8)
3.2
(24.0
)
Net Income
$
249.5
9.2
%
$
163.9
6.9
%
Earnings per Share from Continuing Operations:
Basic
$
.59
$
.44
Diluted
$
.56
$
.42
Earnings per Share:
Basic
$
.60
$
.39
Diluted
$
.57
$
.37
Weighted Average Shares:
Basic
418.0
424.0
Diluted
437.2
446.5
Reconciliation of Adjusted Operating Income and Adjusted
Operating Margin
GAAP Operating Income (a)
$
330.2
12.2
%
$
243.0
10.2
%
Cost of Revenues Charges (c)
0.2
0.0
%
11.2
0.5
%
Restructuring and Other Costs (Income), Net (d)
(5.4
)
-0.2
%
8.3
0.3
%
Amortization of Acquisition-related Intangible Assets
151.6
5.6
%
142.1
6.0
%
Adjusted Operating Income (b)
$
476.6
17.6
%
$
404.6
17.0
%
Reconciliation of Adjusted Net Income
GAAP Net Income (a)
$
249.5
9.2
%
$
163.9
6.9
%
Cost of Revenues Charges (c)
0.2
0.0
%
11.2
0.5
%
Restructuring and Other Costs (Income), Net (d)
(5.4
)
-0.2
%
8.3
0.3
%
Amortization of Acquisition-related Intangible Assets
151.6
5.6
%
142.1
6.0
%
Amortization of Acquisition-related Intangible Assets –
Equity Investments
0.7
0.0
%
0.1
0.0
%
Provision for Income Taxes (e)
(46.4
)
-1.7
%
(58.5
)
-2.5
%
Discontinued Operations, Net of Tax
(3.2
)
-0.1
%
24.0
1.0
%
Adjusted Net Income (b)
$
347.0
12.8
%
$
291.1
12.2
%
Reconciliation of Adjusted Earnings per Share
GAAP EPS (a)
$
0.57
$
0.37
Cost of Revenues Charges, Net of Tax (c)
-
0.01
Restructuring and Other Costs (Income), Net of Tax (d)
-
0.01
Amortization of Acquisition-related Intangible Assets, Net of Tax
0.23
0.21
Amortization of Acquisition-related Intangible Assets, Net of Tax –
Equity Investments
-
-
Provision for Income Taxes (e)
-
-
Discontinued Operations, Net of Tax
(0.01
)
0.05
Adjusted EPS (b)
$
0.79
$
0.65
Segment Data (f)
Three Months Ended
(In millions except percentage amounts)
June 28,2008
% ofRevenues
June 30,2007
% ofRevenues
Revenues
Analytical Technologies
$
1,160.6
42.8
%
$
1,020.4
42.8
%
Laboratory Products and Services
1,656.4
61.1
%
1,449.7
60.8
%
Eliminations
(107.4
)
-3.9
%
(84.2
)
-3.6
%
Consolidated Revenues
$
2,709.6
100.0
%
$
2,385.9
100.0
%
Operating Income and Operating Margin
Analytical Technologies
$
245.1
21.1
%
$
201.9
19.8
%
Laboratory Products and Services
231.5
14.0
%
202.7
14.0
%
Subtotal Reportable Segments
476.6
17.6
%
404.6
17.0
%
Cost of Revenues Charges (c)
(0.2
)
0.0
%
(11.2
)
-0.5
%
Restructuring and Other Income (Costs), Net (d)
5.4
0.2
%
(8.3
)
-0.3
%
Amortization of Acquisition-related Intangible Assets
(151.6
)
-5.6
%
(142.1
)
-6.0
%
GAAP Operating Income (a)
$
330.2
12.2
%
$
243.0
10.2
%
(a) "GAAP" (reported) results were determined in accordance with
U.S. generally accepted accounting principles (GAAP).
(b) Adjusted results are non-GAAP measures and exclude certain
charges to cost of revenues (see note (c) for details); amortization
of acquisition-related intangible assets; restructuring and other
costs, net (see note (d) for details); certain other gains or losses
that are either isolated or cannot be expected to occur again with
any regularity or predictability; the tax consequences of the
preceding items (see note (e) for details); and results of
discontinued operations.
(c) Reported results in 2008 include $0.2 of accelerated
depreciation on manufacturing assets to be abandoned due to facility
consolidations. Reported results in 2007 include $11.2 primarily for
charges for the sale of inventories revalued at the date of
acquisition.
(d) Reported results in 2008 and 2007 include restructuring and
other costs, net, consisting principally of severance, abandoned
facility and other expenses of real estate consolidation and in
2008, gain on pension plan curtailment and loss on a pre-acquisition
litigation-related matter.
(e) Reported provision for income taxes includes $46.4 and $58.5
of incremental tax benefit in 2008 and 2007, respectively, for the
pre-tax reconciling items between GAAP and adjusted net income.
(f) During the first quarter of 2008, the company transferred
management responsibility for several small business units between
segments. Segment information for 2007 has been reclassified to
reflect these transfers.
Notes:
Consolidated depreciation expense in 2008 and 2007 is $48.2 and
$45.0, respectively.
Consolidated equity compensation expense included in both reported
and adjusted results is $16.7 and $12.3 in 2008 and 2007,
respectively.
Consolidated Statement of Income (unaudited) (a)(b)
Six Months Ended
(In millions except per share amounts)
June 28,2008
% ofRevenues
June 30,2007
% ofRevenues
Revenues
$
5,263.6
$
4,724.1
Costs and Operating Expenses:
Cost of revenues (c)
3,094.7
58.8
%
2,847.2
60.3
%
Selling, general and administrative expenses
1,119.6
21.3
%
1,025.9
21.7
%
Amortization of acquisition-related intangible assets
302.8
5.8
%
281.4
6.0
%
Research and development expenses
126.4
2.4
%
118.5
2.5
%
Restructuring and other costs (income), net (d)
(0.5
)
-0.1
%
15.7
0.3
%
4,643.0
88.2
%
4,288.7
90.8
%
Operating Income
620.6
11.8
%
435.4
9.2
%
Interest Income
25.2
19.5
Interest Expense
(67.0
)
(70.4
)
Other Income, Net (e)
6.3
3.5
Income from Continuing Operations Before Income Taxes
585.1
388.0
Provision for Income Taxes (f)
(105.4
)
(61.3
)
Income from Continuing Operations
479.7
326.7
Income from Discontinued Operations (net of income tax provision
of $0.1 in 2007)
-
0.1
Gain (Loss) on Disposal of Discontinued Operations (includes
income tax provision of $1.9 and $1.8)
2.8
(24.0
)
Net Income
$
482.5
9.2
%
$
302.8
6.4
%
Earnings per Share from Continuing Operations:
Basic
$
1.15
$
.77
Diluted
$
1.10
$
.74
Earnings per Share:
Basic
$
1.15
$
.72
Diluted
$
1.10
$
.68
Weighted Average Shares:
Basic
417.8
422.0
Diluted
436.7
443.8
Reconciliation of Adjusted Operating Income and Adjusted
Operating Margin
GAAP Operating Income (a)
$
620.6
11.8
%
$
435.4
9.2
%
Cost of Revenues Charges (c)
0.8
0.0
%
47.6
1.0
%
Restructuring and Other Costs (Income), Net (d)
(0.5
)
-0.1
%
15.7
0.3
%
Amortization of Acquisition-related Intangible Assets
302.8
5.8
%
281.4
6.0
%
Adjusted Operating Income (b)
$
923.7
17.5
%
$
780.1
16.5
%
Reconciliation of Adjusted Net Income
GAAP Net Income (a)
$
482.5
9.2
%
$
302.8
6.4
%
Cost of Revenues Charges (c)
0.8
0.0
%
47.6
1.0
%
Restructuring and Other Costs (Income), Net (d)
(0.5
)
-0.1
%
15.7
0.3
%
Amortization of Acquisition-related Intangible Assets
302.8
5.8
%
281.4
6.0
%
Amortization of Acquisition-related Intangible Assets –
Equity Investments
1.4
0.0
%
0.1
0.0
%
Other Income, Net (e)
(9.8
)
-0.1
%
-
0.0
%
Provision for Income Taxes (f)
(105.6
)
-2.0
%
(118.9
)
-2.5
%
Discontinued Operations, Net of Tax
(2.8
)
-0.1
%
23.9
0.5
%
Adjusted Net Income (b)
$
668.8
12.7
%
$
552.6
11.7
%
Reconciliation of Adjusted Earnings per Share
GAAP EPS (a)
$
1.10
$
0.68
Cost of Revenues Charges, Net of Tax (c)
-
0.07
Restructuring and Other Costs (Income), Net of Tax (d)
-
0.03
Amortization of Acquisition-related Intangible Assets, Net of Tax
0.47
0.42
Amortization of Acquisition-related Intangible Assets, Net of Tax –
Equity Investments
-
-
Other Income, Net of Tax (e)
(0.01
)
-
Provision for Income Taxes (f)
(0.02
)
-
Discontinued Operations, Net of Tax
(0.01
)
0.05
Adjusted EPS (b)
$
1.53
$
1.25
Segment Data (g)
Six Months Ended
(In millions except percentage amounts)
June 28,2008
% ofRevenues
June 30,2007
% ofRevenues
Revenues
Analytical Technologies
$
2,248.0
42.7
%
$
2,008.7
42.5
%
Laboratory Products and Services
3,224.8
61.3
%
2,883.2
61.0
%
Eliminations
(209.2
)
-4.0
%
(167.8
)
-3.5
%
Consolidated Revenues
$
5,263.6
100.0
%
$
4,724.1
100.0
%
Operating Income and Operating Margin
Analytical Technologies
$
473.8
21.1
%
$
387.3
19.3
%
Laboratory Products and Services
449.9
14.0
%
392.8
13.6
%
Subtotal Reportable Segments
923.7
17.5
%
780.1
16.5
%
Cost of Revenues Charges (c)
(0.8
)
0.0
%
(47.6
)
-1.0
%
Restructuring and Other Income (Costs), Net (d)
0.5
0.1
%
(15.7
)
-0.3
%
Amortization of Acquisition-related Intangible Assets
(302.8
)
-5.8
%
(281.4
)
-6.0
%
GAAP Operating Income (a)
$
620.6
11.8
%
$
435.4
9.2
%
(a) "GAAP" (reported) results were determined in accordance with
U.S. generally accepted accounting principles (GAAP).
(b) Adjusted results are non-GAAP measures and exclude certain
charges to cost of revenues (see note (c) for details); amortization
of acquisition-related intangible assets; restructuring and other
costs, net (see note (d) for details); certain other gains or losses
that are either isolated or cannot be expected to occur again with
any regularity or predictability (see note (e) for details); the tax
consequences of the preceding items (see note (f) for details); and
results of discontinued operations.
(c) Reported results in 2008 include $0.4 for charges for the sale
of inventories revalued at the date of acquisition and $0.4 of
accelerated depreciation on manufacturing assets to be abandoned due
to facility consolidations. Reported results in 2007 include $47.6
primarily for charges for the sale of inventories revalued at the
date of acquisition.
(d) Reported results in 2008 and 2007 include restructuring and
other costs, net, consisting principally of severance, abandoned
facility and other expenses of real estate consolidation and in
2008, gain on pension plan curtailment and loss on a pre-acquisition
litigation-related matter.
(e) Reported results in 2008 include a $9.8 currency transaction
gain associated with an intercompany financing transaction.
(f) Reported provision for income taxes includes i) $96.0 and $118.9
of incremental tax benefit in 2008 and 2007, respectively, for the
pre-tax reconciling items between GAAP and adjusted net income; and
ii) in 2008, $9.6 of incremental tax benefit from adjusting the
company's deferred tax balances as a result of newly enacted tax
rates in Switzerland.
(g) During the first quarter of 2008, the company transferred
management responsibility for several small business units between
segments. Segment information for 2007 has been reclassified to
reflect these transfers.
Notes:
Consolidated depreciation expense in 2008 and 2007 is $95.8 and
$91.0, respectively.
Consolidated equity compensation expense included in both reported
and adjusted results is $27.7 and $26.1 in 2008 and 2007,
respectively.
Consolidated net capital expenditures in 2008 totaled $103.8.
Condensed Consolidated Balance Sheet (unaudited)
(In millions)
Jun 28, 2008
Dec. 31, 2007
Assets
Current Assets:
Cash and cash equivalents
$
1,006.9
$
625.1
Short-term investments
13.5
14.1
Accounts receivable, net
1,599.1
1,450.0
Inventories
1,264.1
1,169.9
Other current assets
415.9
406.2
Total current assets
4,299.5
3,665.3
Property, Plant and Equipment, Net
1,304.5
1,267.4
Acquisition-related Intangible Assets
6,950.2
7,157.8
Other Assets
408.5
403.7
Goodwill
8,718.3
8,713.2
Total Assets
$
21,681.0
$
21,207.4
Liabilities and Shareholders' Equity
Current Liabilities:
Short-term obligations and current maturities of long-term
obligations
$
145.3
$
149.3
Other current liabilities
1,734.8
1,752.3
Total current liabilities
1,880.1
1,901.6
Other Long-term Liabilities
2,686.4
2,771.6
Long-term Obligations
2,044.5
2,045.9
Total Shareholders' Equity
15,070.0
14,488.3
Total Liabilities and Shareholders' Equity
$
21,681.0
$
21,207.4
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Thermo Fisher Scientific Incmehr Nachrichten
Analysen zu Thermo Fisher Scientific Incmehr Analysen
Aktien in diesem Artikel
Thermo Fisher Scientific Inc | 531,30 | 1,05% |
Indizes in diesem Artikel
S&P 500 | 5 859,84 | -0,99% |